NCT03715309Unknown2 期
R2 in the Treatment of Follicular Lymphoma Grade 1-3A
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 115
- 试验地点
- 1
- 主要终点
- CR
研究概览
简要总结
Lenalidomide Based Immunotherapy in the Treatment of FL
详细描述
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnose as de novo or relapse refractory FL grade 1-3A .
- •No history of stem cell transplantation.
- •Written informed consent.
排除标准
- •Chemotherapy or large field radiotherapy within 3 weeks prior to entering the study.
- •Clinically significant active infection.
- •Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule.
- •Any significant medical or psychiatric condition that might prevent the patient from complying with all study procedures.
- •Subject has ≥grade 2 peripheral neuropathy or grade 1 with pain within 14 days before enrollment.
- •Patients who are pregnant or breast-feeding.
- •HIV infection.
研究组 & 干预措施
Revlimd
Experimental
干预措施: Revlimid (Drug)
结局指标
主要结局
CR
时间窗: 12 weeks
Complete response rate
次要结局
- PFS(1 year)
- OS(1 year)
- ORR(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Frontline Treatment of Follicular Lymphoma with AtezolizUmab and Obinutuzumab with and Without RadiOtherapyFollicular LymphomaNCT04962126Olivia Newton-John Cancer Research Institute15
招募中
1 期
Early Stage Follicular LymphOma and RadioTherapy PLUS anti-CD20 AntibodyEarly Stage Follicular LymphOmaCTIS2023-509278-41-00niversitaetsklinikum Heidelberg AöR130
Unknown
2 期
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) TypeMALT LymphomaNCT00923663Medical University of Vienna16
已完成
2 期
Short Chemo Radio Immunotherapy in Follicular Lymphoma Trial of Y-90 ibritumomab tiuxetan (Zevalin®) as therapy for first and second relapse in follicular lymphomaFollicular lymphomaCancerISRCTN44808098Southampton University Hospitals NHS Trust (UK)50
已完成
2 期
"MIRO" Molecularly Oriented Immuno-radio-therapyFollicular Lymphoma, Grade 1Follicular Lymphoma, Grade 2Follicular Lymphoma Grade 3ANCT02710643Fondazione Italiana Linfomi - ETS110